Is the biology of Ginkgo Bioworks worth $ 15 billion?

“The time should be right when a young technology company can be able to recruit people to write non-magazine articles,” he said. fell Dirk Haussecker, a biotech stockbroker working on Twitter.

Kelly says the magazine was inspired by Think, published by IBM since the 1930s. “Why did he do this? No one knows what a computer is like, “says Kelly, who observes Ginkgo also working as a genetic engineer.

Pa Podcast, journalists with Stat News likened Ginkgo to a “meme stock,” or “stonk,” a regular to ask for money moving in public regardless of starting a business. When the SPAC agreement is finalized – sometime in September – the company will sell it under the price of “DNA,” formerly of Genentech, the world’s first professional genius. “Ginkgo Bioworks should not use a DNA ticker,” said stock exchange Adam Feuerstein.

The SPACs are a Wall Street Events which gives the IPO a way to take into account the company’s financial performance. Will Gornall, a professor of business school at the University of British Columbia, believes it enables women to access hot spots but also to see corporate profits. Some do, such as who publicly acquired Richard Branson’s space company Virgin Galactic Holdings, has done well, but the five electric car companies that came out publicly through SPAC were criticized by what Bloomberg called “cruel”Repair.

Gornall could see the bettor’s mind on Ginkgo’s game. In recent years corporate market profits have been driven by a handful of companies, including Amazon, Apple, Facebook, Google, and Microsoft – each now valued at more than a trillion dollars. “It would be wise to calculate if there is a 1% chance that biology is the next computer and this is the company that is achieving this,” says Gornall.

Sales of third parties

Since its inception, Ginkgo has spent nearly half a billion dollars, most of which are building robotic laboratories, genetic controllers and state-of-the-art lab equipment such as multiple spectrometers. These “foundries” allow them to test genes that are added to micro-organisms (usually yeast) or other cells. He claims to be able to make 50,000 of these variables in one day. The purpose of the experimental project is to determine which type of gene has been given that may be most effective, that is, converting sugar into a specific drug. Kelly says customers can use Ginkgo’s services instead of just building their own lab.

What’s missing in Ginkgo’s history is any blockbuster thing that comes with research. “If you call yourself ‘synbio’, then it brings a good chance — you’re saying you’re going to the moon,” says Koeris. “You’ve made a lot of money against the exciting vision so soon you have to have some change, whether it’s drugs or corporate madness.”

Meanwhile, Ginkgo’s production of yeast has led to the commercialization of three categories of fragrances, Kelly says. Robert Weinstein, President and CEO of the US arm for product development and Robertet, confirmed that his company is now making the two molecules using a yeast produced by Kelly’s company. One, gamma-decalactone, has a strong peach odor. One, massoia lactone, is a clear liquid that is often located away from the trunk of a tropical tree; used as a perfume, they can sell online for $ 1,200 kg. A year-round run could produce a unique multi-million dollar product.

For George Church, a professor at Harvard Medical School, the theory is not based on the promise that biological engineering would revolutionize production. “I think perfume and perfume are very different from the vision that biology can make anything,” says Church. Kelly sometimes struggles to reconcile the “disruptive” potential she sees in biology with Ginkgo’s achievements. The church showed me May report in the Boston Globe about the combination of Ginkgo and Rising Eagle. In it, Kelly said her company was a good investment because the world is known for its great potential for biology production, citing a covid-19 vaccine made from messenger RNA and animal-free proteins in new packages, such as the non-food.

“The story was a list of things they did, but the most rewarding came from others,” says Church. “That doesn’t seem to add $ 15 billion to me.” However, Church members are hoping for Ginkgo’s victory. Not only is the company its own “rhinoceros”, but also found the rest Some of the original products he made when he was a freshman (he also sold the company to Zymergen). The way Ginkgo will work in the future “could benefit our entire community or harm our entire region,” he says.

Although Ginkgo’s work has not led to blockbusters, and Kelly allows it to be “disappointing” that biotech lasts a long time, he says other consumer products are coming soon. The program of Cannos cannabis company Cronos, based in Canada, says that by the end of the year he will be selling pineapple-sweetened candy bars containing CBG, a portion of marijuana flowers; Ginkgo helped to show how they make compost and yeast. Exit from Ginkgo, called Motif FoodWorks, he says is also expected to re-create the animal flavor that it can produce this year.